Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parmax PharmaBOM:540359 +1.99%39 Days Inventory is 220.15 as of Mar. 2026, which is 87% above its 10-year median of 117.91. GuruFocus rates BOM:540359 with a GF Score™ of 39/100 and a GF Value™ of ₹25.56 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 921 Drug Manufacturers companies, Parmax Pharma ranks worse than 54.61% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Parmax Pharma's Average Total Inventories for the
three
months ended in Mar. 2026 was ₹78.5 Mil. Parmax Pharma's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹32.5 Mil.
Hence, Parmax Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 220.15.
The historical rank and industry rank for Parmax Pharma's Days Inventory or its related term are showing as below:
BOM:540359'
s Days Inventory Range Over the Past 10 Years
Min: 48.38 Med: 117.91 Max: 206.14
Current: 175.46
During the past 13 years, Parmax Pharma's highest Days Inventory was 206.14. The lowest was 48.38. And the median was 117.91.
BOM:540359's Days Inventory is ranked worse than 54.61% of 921
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs BOM:540359: 175.46
Parmax Pharma's Days Inventory
increased
from Mar. 2025 (81.54) to Mar. 2026 (220.15).
It might indicate that Parmax Pharma's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Parmax Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.41.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Parmax Pharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 2.37.
Parmax Pharma (BOM:540359) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Parmax Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Parmax Pharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Parmax Pharma Days Inventory Related Terms
Parmax Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Parmax Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540359 vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parmax Pharma (BOM:540359) has a Days Inventory of 220.15 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Parmax Pharma and its competitors. This is 87% above median its historical median of 117.91. Over the past decade, Parmax Pharma's Days Inventory has ranged from 48.38 to 206.14. According to the industry distribution chart, Parmax Pharma ranks #503 out of 921 companies in the Drug Manufacturers industry, placing it in the top 54.6%.
Is Parmax Pharma's Days Inventory too high?
Parmax Pharma's current Days Inventory of 220.15 is 87% above median its 10-year median of 117.91. Over the past 10 years, this metric has ranged from a low of 48.38 to a high of 206.14. The Drug Manufacturers industry median Days Inventory is 164.48. Parmax Pharma's value of 220.15 is 33.8% above this industry median. Based on the distribution chart, Parmax Pharma ranks #503 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Parmax Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #503 out of 921 companies for Days Inventory. This places Parmax Pharma in the lower half of its industry. The industry median Days Inventory is 164.48. Parmax Pharma's value of 220.15 is 33.8% above this benchmark. Historically, Parmax Pharma's own Days Inventory has ranged from 48.38 to 206.14 over the past decade. While the company's 10-year median is 117.91 vs. the industry median of 164.48, Parmax Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parmax Pharma's current Days Inventory of 220.15 is 33.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current Days Inventory is 220.15, which is 87% above median its own 10-year median of 117.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹25.56, compared to a current price of ₹104.97 — trading 310.7% above its estimated fair value. The current Days Inventory is 220.15, which is 87% above median its 10-year median of 117.91 and 33.8% above the Drug Manufacturers industry median of 164.48. Parmax Pharma's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current Days Inventory is 220.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹104.97 is trading 310.7% above its estimated GF Value™ of ₹25.56.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
Days Inventory: 220.15 (87% above median its 10-year median of 117.91)
GF Value™: ₹25.56 vs. price of ₹104.97 (310.7% above fair value)
Industry Position: 33.8% above the Drug Manufacturers median (#503 of 921)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
